About KCJ
Kidney Cancer Journal is a quarterly peer-reviewed cancer journal reaching more than 12,500 oncology and urology clinicians. Kidney Cancer Journal is the official Journal of the Kidney Cancer Association. The objective of KCJ is to serve as the most comprehensive, peer-reviewed resource of information for physicians on the diagnosis and treatment of renal cell carcinoma and its tumor types. KCJ supports the mission of the Kidney Caner Association by facilitating the knowledge transfer, contributing to cancer prevention, early detection, diagnosis, and cure of kidney cancer. KCJ publishes original articles, reviews, clinical case studies as well as letters to the editor. KCJ provides editorial content encompassing a wide array of topics relevant and useful to the fields of oncology and journal contents are directed by the potential insights of today’s Key Opinion Leaders in oncology around the world.
Kidney Cancer Journal is the only peer-reviewed medical journal and most comprehensive source of scientific information focusing exclusively on renal cell carcinoma. In addition, special reports and supplements covering ASCO meeting and highlights from the annual International Kidney Cancer Association Meeting also published. KCJ is distributed as a complimentary professional service to approximately 12,300 physicians, including all medical oncologists and targeted urologists. KCJ utilizes a Medical Advisory Board and Editorial Advisory Board of more than 30 oncologists/physicians who are leading investigators in this field. Archives available through the KCJ website here and also KCA’s website at www.kidneycancer.org
EDITORIAL BOARD
Editor-in-Chief
Robert A. Figlin, MD, FACPSteven Spielberg Family Chair in Hematology Oncology Professor of Medicine and Biomedical Sciences Director, Division of Hematology Oncology Deputy Director, Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center Los Angeles, California
Medical Advisory Board
Michael B. Atkins, MDDeputy Chief, Division of Hematology-Oncology Director, Cancer Clinical Trials Office Beth Israel Deaconess Medical Center Leader, Renal Cancer Program, Dana Farber Harvard Cancer Center Boston, Massachusetts
Ronald M. Bukowski, MDDirector, Department of Experimental Therapeutics Cleveland Clinic Taussig Cancer Center Cleveland, Ohio
Christopher G. Wood, MDAssociate Professor, Departments of Urology and Cancer Biology University of Texas M.D. Anderson Cancer Center Houston, Texas
Robert J. Motzer, MDAttending Physician, Memorial Sloan-Kettering Cancer Center New York City Professor of Medicine Weill Medical College of Cornell University Ithaca, New York
Walter M. Stadler, MDFred C. Buffett Professor Departments of Medicine and Surgery Sections of Hematology-Oncology and Urology University of Chicago Medical Center Chicago, Illinois
Nurse Advisory Board
Nancy Moldawer, RN, MSNNursing Director City of Hope Kidney Cancer Program City of Hope Comprehensive Cancer Center Duarte, California
Laura Wood, RN, MSN, OCNRenal Cancer Research Coordinator Cleveland Clinic Taussig Cancer Center Cleveland, Ohio
Patient Advocate
Gretchen E. VaughanChief Executive Officer Kidney Cancer Association
Publishing Staff
- Senthil Samy, PhD.,Executive Editors
- Vinu Jyothi, MD, MPH., Assoc. Director, Editorial Services
- Stu Chapman,Editorial Consultant
- Susan Hirschhaut,Director of Advertising and Strategic Initiatives
- Michael McClain,Design Director
Editorial Offices
517 Belle Gate Pl Cary NC 27519Copyright 2020 BioMedz Global LLC All rights reserved. None of the contents may be reproduced in any form without the permission of the publisher.
Editorial Advisory Board
Arie Belldegrun, MDDavid Geffen School of Medicine at UCLA Los Angeles, California
Steven Campbell, MDCleveland Clinic Foundation Cleveland, Ohio
Janice P. Dutcher, MDOur Lady of Mercy Medical Center Comprehensive Cancer Center Bronx, New York
Timothy Eisen, MDRoyal Marsden Hospital London, UK
Paul Elson, PhDCleveland Clinic Foundation Cleveland, Ohio
Bernard Escudier, MDInstitut Gustave-Roussy Villejuif, France
James H. Finke, PhDCleveland Clinic Lerner College of Medicine of Case Western Reserve University Cleveland, Ohio
Keith Flaherty, MDAbramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania
Daniel J. George, MDDuke Clinical Research Institute Durham, North Carolina
Martin Gore, MDRoyal Marsden Hospital London, UK
Gary Hudes, MDFox Chase Cancer Center Philadelphia, Pennsylvania
Thomas Hutson, DO, PharmDBaylor University Medical Center Dallas, Texas
Eric Jonasch, MDUniversity of Texas MD Anderson Cancer Center Houston, Texas
Eugene D. Kwon, MDMayo Clinic Rochester, Minnesota
Bradley C. Leibovich, MDMayo Clinic Rochester, Minnesota
Kim A. Margolin, MDCity of Hope National Medical Center Duarte, California
David Nanus, MDNew York Presbyterian Hospital- Weill Cornell Medical Center New York, New York
Andrew C. Novick, MDCleveland Clinic Foundation Cleveland, Ohio
Leslie Oleksowicz, MDCollege of Medicine University of Cincinnati Medical Center Cincinnati, Ohio
Allan Pantuck, MDDavid Geffen School of Medicine at UCLA Los Angeles, California
Brian Rini, MDVanderbilt-Ingram Cancer Center Vanderbilt University Medical Center Nashville, Tennessee
Paul Russo, MDMemorial Sloan-Kettering Cancer Center New York, New York
Ihor S. Saczuk, MDHackensack University Medical Center Hackensack, New Jersey
Domenic A. Sica, MDMedical College of Virginia Richmond, Virginia
Jeffrey A. Sosman, MDVanderbilt University Medical Center Vanderbilt-Ingram Cancer Center Nashville, Tennessee
David Swanson, MDUniversity of Texas MD Anderson Cancer Center Houston, Texas
Nicholas J. Vogelzang, MDNevada Cancer Institute Las Vegas, Nevada